Pembrolizumab and chemoradiotherapy in locally advanced cervical cancer

In this randomized, double-blind, placebo-controlled Phase 3 clinical trial, 1,060 adult women with newly diagnosed, high-risk, locally advanced cervical cancer were followed at 176 medical centers in 30 countries. They were assigned to receive either pembrolizumab/chemoradiotherapy or placebo/chemoradiotherapy. Median follow-up was 17.9 months in both treatment groups. Progression-free survival rates at 24 months were 68% in the pembrolizumab/chemoradiotherapy arm versus 57% in the placebo/chemoradiotherapy arm. Overall survival at 24 months was 87% in the pembrolizumab/chemoradiotherapy group and 81% in the placebo/chemoradiotherapy group.